Evaluation of Relative Bioavailability of D-0502 Tablet in Healthy Female Subjects
NCT ID: NCT05226338
Last Updated: 2022-08-08
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1
18 participants
INTERVENTIONAL
2021-10-27
2022-05-11
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Study in Healthy Adult Female Subjects
NCT05339633
A Study to Evaluate the Drug Exposure of Single Ascending Doses of BMS-986369 and the Effect of Food on the BMS-986369 in Healthy Participants
NCT05350800
OPEN LABEL, 2-PERIOD STUDY, TO COMPARE BIO-AVAILABILITY OF 2 DIFFERENT FORMULATIONS OF PF-05221304 IN HEALTHY ADULTS
NCT03871439
Safety and Efficacy Study of Orally Administered DS102 in Healthy Subjects
NCT02673593
To Evaluate Effect of Food of DA-5222 in Healthy Adult Subjects
NCT06993168
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Sequence 1
3 period, 3 dose level
D-0502
Formulation 1 Formulation 2 Formulation 3
Sequence 2
3 period, 3 dose level
D-0502
Formulation 1 Formulation 2 Formulation 3
Sequence 3
3 period, 3 dose level
D-0502
Formulation 1 Formulation 2 Formulation 3
Sequence 4
3 period, 3 dose level
D-0502
Formulation 1 Formulation 2 Formulation 3
Sequence 5
3 period, 3 dose level
D-0502
Formulation 1 Formulation 2 Formulation 3
Sequence 6
3 period, 3 dose level
D-0502
Formulation 1 Formulation 2 Formulation 3
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
D-0502
Formulation 1 Formulation 2 Formulation 3
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Required evaluation by Investigator for screening and enrollment
* Agreement and compliance with the study and follow-up procedures
Exclusion Criteria
* Pregnant or nursing women
18 Years
55 Years
FEMALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
InventisBio Co., Ltd
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Labcorp Clinical Research Unit
Daytona Beach, Florida, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
D0502-104
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.